GLYC - GLYCOMIMETICS INC
IEX Last Trade
0.2404
0.074 30.948%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$0.17
0.07
44.82%
Fundamental analysis
25%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
25%
Performance
5 Days
3.46%
1 Month
-15.74%
3 Months
51.72%
6 Months
-26.67%
1 Year
-90.47%
2 Year
-89.34%
Key data
Stock price
$0.24
DAY RANGE
$0.17 - $0.23
52 WEEK RANGE
$0.15 - $3.53
52 WEEK CHANGE
-$90.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/01/2024
Company detail
CEO: Harout Semerjian
Region: US
Website: glycomimetics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: glycomimetics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.
Recent news